The landscape of modern immunological research has been significantly shaped by the study of cancer-tes by MAJ de Rooij · 2022 · Cited by 20 — Most peptides originated from MAGE-A1 (11 peptides), followed by MAGE-A9 (seven peptides) and MAGE-A3 (six peptides). We did not identify peptides from MAGE-C1. tis antigens (CTAs). Among these, the mage a1 peptide occupies a central position in contemporary laboratory investigations. As a member of the MAGE family, specifically the MAGEA1 (MAGE Family Member A1) gene product, this protein has become a cornerstone in the development of specialized investigative tools.
What is the MAGE-A1 Peptide?
The mage a1 peptide refers to specific amino acid sequences derived from the MAGEA1 protein. These peptides, such as the well-documented MAGE-A1 (278–286) epitope, are frequently employed in controlled laboratory settings. Because MAGE-A proteins are a subclass of cancer/testis (CT) antigens—which are generally restricted to male germ line cells and the placenta under normal physiological conditions—their by Y Mao · 2019 · Cited by 58 — Taken together, our data suggest that MAGE-A1 is a promising candidate marker for LUAD therapy and the MAGE-A1-specific CAR-T cell immunotherapy presence in various 335 Discovery and characterization of MAGE-A1-specific tumor types makes them unique subjects for study.
In research environments, the mage a1 peptide is widely used to stimulate human MAGE-A1-specific CD8+ T cells. By utilizing a high quality epitope peptide, researchers can effectively monitor T cell responses in vitro. For instance, the PepTivator MAGE-A1, which consists of a pool of lyophilized peptides, is often utilized for comprehensive T cell monitoring, allowing for a broader range of MHC allele coverage.
Research Significance and Clinical Associations
The expression patterns of MAGEA1 are of particular interest to the scientific community. Data indicates that the MAGEA1 gene is expressed in many tumors of several types, including melanoma, head and neck squamous cell carcinoma, and breast carcinoma. Notably, it is expressed in about 50% of multiple myeloma cases and up to 60% in triple-negative breast cancer.
Furthermore, current studies highlight that:
* MAGE-A1 in lung adenocarcinoma is considered a promising candidate marker for LUAD therapy.
* The identification of the predicted tumor-associated peptide MAGE-A1 278–286 has been fundamental in understanding how these sequences are presented by human MHC-I molecules.
* MAGEA1 modulators represent a promising avenue for cancer treatment in experimental models, aiming to l MAGE-A Antigens and Cancer Immunotherapy everage the specificity of these antigens.
Practical Applications in Immunological Studies
When conducting research, scientists often rely on standardized reagents to ensure reproducibility. The human MAGE-A1 peptide pool for T cell monitoring is an essential asset for those studying the compl Avidity optimization of a MAGE‐A1‐specific TCR with exities of tumor immunity. These peptides can be used in the study of tumor immunity to better characterize the interaction between epitopes and T cell receptors (TCRs).
It is important to note that the mage a1 peptide is recognized as a member of the MAGE gene family, characterized by highly conserved MAGE homology domains (MHDs). Because MAGE-A antigens are expressed in a variety of cancers of diverse histological origin, they serve as a reliable baseline for comparing immune responses.
Observation Jun 21, 2024 — MAGEA1 modulators represent a promising avenue for cancer treatment owing to their ability to specifically target cancer cells while sparing normal tissues. s on Methodology
In my own review of laboratory protocols, the precision of peptide selection is paramount. Using purified, high-quality synthesized peptides ensures that the resulting data—whether regarding TCR avidity or epitope screening—is robust. The versatility of these tools, which cover a broad range of different MHC alleles, allows for high-throughput screening that was not possible in earlier decades.
While the clinical potential of these antigens remains a subject of intense investigation, the utility of the mage a1 peptide in foundational research is well-established. By focusing on the molecular characteristics of MAGEA1 and its derivatives, researchers by BJ Cameron · 2013 · Cited by 887 — A peptide from the muscle protein Titin (ESDPIVAQY) was identified as an alternative target for the MAGE A3 TCR and the most likely cause of in vivo toxicity. continue to refine our understanding of how specific protein sequences are recognized and processed within the framework of cellular immunology. As we move forward, the continued characterization of these peptides will undoubtedly remain a focal point for those exploring the intricate mechanisms of the immune system.